1. IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE‐BLIND RANDOMIZED CLL12 TRIAL. (12th June 2019) Authors: Langerbeins, P.; Bahlo, J.; Rhein, C.; Gerwin, H.; Cramer, P.; Fürstenau, M.; Al‐Sawaf, O.; von Tresckow, J.; Fink, A.M.; Kreuzer, K.; Vehling‐Kaiser, U.; Tausch, E.; Müller, L.; Eckart, M.; Schlag, R.; Freier, W.; Gaska, T.; Balser, C.; Reiser, M.; Stauch, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study – AIO SUP-0108. (August 2016) Authors: Jordan, K.; Luetkens, T.; Gog, C.; Killing, B.; Arnold, D.; Hinke, A.; Stahl, M.; Freier, W.; Rüssel, J.; Atanackovic, D.; Hegewisch-Becker, S. Journal: European journal of cancer Issue: Volume 63(2016) Page Start: 127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗